Cyclacel Pharmaceuticals (NASDAQ:CYCC) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report published on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Roth Capital downgraded Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Stock Up 6.9 %

NASDAQ CYCC opened at $0.33 on Tuesday. Cyclacel Pharmaceuticals has a fifty-two week low of $0.30 and a fifty-two week high of $4.00. The stock has a market cap of $2.06 million, a price-to-earnings ratio of -0.03 and a beta of 0.35. The business has a fifty day moving average of $0.36 and a 200-day moving average of $0.73.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.36. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 18,150.00%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.